Leading the Way in Life Science Technologies

GEN Exclusives

More »
Regional Development - Related Content
  • Insight & Intelligence™
  • More »
  • BIOTECHNOLOGY IN SPAIN
    - Interview with José María Fernández Sousa-Faro, Ph.D., President of the Spanish Association of Bioenterprises (ASEBIO), and Chairman of the Zeltia Group
  • (BIO) BANKING IN LUXEMBOURG
    - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
  • CHINA'S CHANGING PHARMACEUTICAL LANDSCAPE
    - Interview with Michael Keech, Director, Pharmaceutical and Life Sciences Advisory Services Group, PricewaterhouseCoopers
  • BIOTECHNOLOGY IN GEORGIA
    - Interview with Charles Craig, President of Georgia Bio; Stephen Hill, President, Solvay Pharmaceuticals, Inc.; and Russell Medford, M.D., Ph.D., President and CEO, Atherogenics, Inc.
  • MAKING NEW YORK CITY A BIO-MECCA
    - Lenzie Harcum, Vice President of Business Development in Biosciences at the New York City Economic Development Corporation, and Bill Fair, Managing Director at Alexandria Real Estate Equities

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »